Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


Recent News
Archived Press Releases
SEC Filings
Printed Material
Newsletter Signup



 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail as well as corporate materials mailed to you.

Recent News:

 

11/18/2008 Hemispherx Enters Major Contract with Lovelace Respiratory Institute
…..Projected New Data to Enhance Ampligen® NDA Filing Status in Chronic Fatigue Syndrome

11/10/2008 HEMISPHERX BIOPHARMA, INC. RELEASES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2008
….Net Loss Reduced 40% over Prior Year

10/28/2008 Hemispherx Selected to Present at 7th Annual BIO Investor Forum
…..Showcases Leading Growth Companies in Life Sciences

10/28/2008 Hemispherx Selected to Present at 7th Annual BIO Investor Forum
…..Showcases Leading Growth Companies in Life Sciences

10/27/2008 Immune Adjuvants and Cancer Vaccines: Hemispherx’s New Enhancement Strategy
…….To be Unveiled at Upcoming 23rd Annual Biotherapy Conference

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants
 McGladrey & Pullen, LLP

Number of Shares of Common Stock
As of August 7, 2007 there were 72,826,971 shares of Hemispherx common stock issued and outstanding. If you need additional assistance or information regarding the company, contact Hemispherx Biopharma’s Investor Relations representative. 

Investor Relations:

Dianne Will
Phone:  518-398-6222
Fax:  518-398-6369
or send an e-mail to:
ir@hemispherx.net

 

 

 

Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.